Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

9.380 +0.910 (+10.74%)
Streaming Delayed Price Updated: 3:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax Inc

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
$1000 Invested In Novavax 5 Years Ago Would Be Worth This Much Today
Via Benzinga
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and... 
Via Benzinga
Exposures COVID-19
Should You Buy Novavax Stock After This Regulatory Win?
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
Why Are Novavax Shares Trading Lower Today?
Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you need to know. 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Here's a look at five stocks that saw increased attention from Benzinga readers during the week and the reasons why. 
Via Benzinga
How Is The Market Feeling About Novavax?
Via Benzinga
Looking Into Novavax's Recent Short Interest
Via Benzinga
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?
Regulators recently approved an updated COVID shot from Novavax. 
Via The Motley Fool
Exposures COVID-19
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
FDA Approves Novavax's Updated COVID Vaccine Targeting Currently Circulating Variants
The FDA granted Emergency Use Authorization to Novavax's updated COVID-19 vaccine for individuals aged 12 and older. The vaccine, included in CDC recommendations, will soon be available nationwide.... 
Via Benzinga
Exposures COVID-19 Product Safety
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
Don't be too quick to jump on the Wall Street bandwagon. 
Via The Motley Fool
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to... 
Via Benzinga
Exposures COVID-19 Product Safety
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Its 12-month relative strength performance is impressive, but Novavax now faces resistance. 
Via Investor's Business Daily
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
Exposures COVID-19 Product Safety
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
Exposures COVID-19
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $0.99, below expectations. The company revised its 2024 revenue guidance to... 
Via Benzinga
Exposures COVID-19
NVAX Stock Earnings: Novavax Misses EPS, Beats Revenue for Q2 2024
NVAX stock results show that Novavax missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 3
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of July 29 through Aug. 2. 
Via Talk Markets
Where Will Novavax Be in 5 Years?
Its been a good year so far for the biotech, but how long can it keep the momentum going? 
Via The Motley Fool
What's Going On With Novavax (NVAX) Stock?
Novavax shares are trading lower by 5.5% Thursday morning. Shares of several vaccine makers are trading lower after Moderna revised its 2024 expectations. 
Via Benzinga
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
Moderna delivered nearly double the sales analysts expected in the second quarter. 
Via Investor's Business Daily
JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024
Analysts from JPMorgan Chase have expressed their concern about the outlook for these stocks with lowered price targets. 
Via InvestorPlace
JPMorgan Just Issued a Warning on Novavax (NVAX) Stock
Novavax has inked a key vaccine deal with Sanofi, but NVAX stock is down after JPMorgan warned about overvaluation concerns. 
Via InvestorPlace
Stocks Mixed After Job Openings, Consumer Data
Stocks are mixed midday, as the Federal Reserve's two-day policy meeting gets underway, with plenty of earnings and economic data for Wall Street to unpack in the meantime. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.